19 Nov 03
Pharma NewsBytes selects out what we consider as being some of the most interesting press releases to have appeared on our DailyUpdates tracking service over the past few weeks. Currently featured new items focus on development activity in the field of rheumatoid arthritis; advances in anti-hyperlipemia therapeutics; and the termination of MK-0869 development for the treatment of depression
04 Nov 03
It is predicted that the annual value of the market for drugs used to treat autoimmune disease will exceed $20 billion in the next few years. Rheumatoid arthritis is one of the more common and difficult to treat autoimmune diseases and there is a great deal of interest in the discovery of novel drugs to treat this condition. This comprehensive report evaluates breaking drug discovery targets and therapeutic candidates for the treatment of this disease
21 Oct 03
Emerging Drug Discovery Targets" provides a twice monthly summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. This edition of features data highlighting technology for improved wound healing; a new candidate asthma treatment; a novel approach to diabetes and combination therapy offering improved radiotherapy responsiveness. As usual we also provide updates on industrial advances and licensing opportunities.
21 Oct 03
It is clear that the UK biotechnology industry is undergoing widespread consolidation, driven by difficulties in raising capital to fund research programmes.
Dr Christopher Baxter-Jones and Mark Sharp
15 Oct 03
One of the most controversial issues in international healthcare is the practice of parallel trade of pharmaceuticals. Parallel trade, sometimes known as the 'grey market', involves the cross border trade in a given product in parallel to a manufacturer's official main supply chain in that country.
15 Oct 03
Worldwide, 95 million people suffer from wounds that result in tissue loss. Wound healing problems extend hospital stays, especially in the elderly, resulting in an additional $1.5 billion in healthcare costs in the US alone. LeadDiscovery’s current target of the month focuses on connexin43, blocking of which produces a dramatic improvement in wound healing. In this feature we also describe how antisense technology has been applied to develop a licensing opportunity in this area
15 Oct 03
Pharma NewsBytes is LeadDiscovery’s selection of recent press releases for the drug development. Currently featured news items include those announcing promising clinical data for Antigenics' pancreatic cancer Oncophage vaccine; FDA backing for Forest's new Alzheimer's disease drug, Memantine; early figures on the sale of AstraZeneca's anti-cholerstremic drug Crestor; and FDA approval of Pfizer's potential blockbuster, Inspira for the treatment of congestive heart failure
01 Oct 03
"Emerging Drug Discovery Targets" summarizes the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. This edition explores recent advances in the use of siRNA technology in oncology, new molecular targets for the treatment of diabetes and advances in the development of GSK-3 inhibitors. Recent preselected press releases are also highlighted and as usual new licensing opportunities, breaking publications and new industry reports are all identified.
25 Sep 03
Proof of concept studies have accumulated supporting the targeting of glycogen synthase kinase-3 (GSK-3) for the treatment of diabetes and CNS conditions. Now inhibitors are emerging as therapeutic candidates
23 Sep 03
"Ghrelin: Pharmaceutical & Therapeutic Opportunities for the Treatment of Obesity" represents a cutting edge analysis of why and how ghrelin should be targeted for the identification of new therapies for obesity
15 Sep 03
As businesses start to get ready for the next up-cycle, new Names Identities and Images are underway. Big time branding failures and silly naming of the recent past taught marketers some key lessons. Here, is a quick guide to test any Name Identity in use or being planned for the upswing.
03 Sep 03
The medical community is quickly evolving its understanding of menopause. Following the abrupt, early halt to the HRT portion of the Women's Health Initiative last July, due to findings that Hormone Replacement Therapy's risks outweighed its benefits, headlines now read
Nancy Lonsdorf M.D.
27 Aug 03
Tim Taylor, Chief Business Development Officer at McLaren, looks at the role that IT can play in the improvement of process automation and control to positively benefit business strategies. An effective information management strategy can support companies, rather than hamper them, enabling them to build an organisation and systems that can manage extended global business applications in a compliant and efficient fashion.
15 Aug 03
Some of the world’s leading drugs, such as Bristol-Myers Squibb’s pravastatin for high cholesterol, TAP’s lansoprazole and Daiichi’s levofloxacin were discovered in Japanese laboratories. With this history of important drug research there is keen interest in biotechnology.
Dr Faiz Kermani
15 Aug 03
The increase in life expectancy coupled with a decreasing birth rate will place considerable pressure on governments and healthcare providers. Governments are having to reassess how they allocate their healthcare spending given that on average, the over 65s require four times as much healthcare resources as younger people.
Dr Faiz Kermani
05 Aug 03
Research towards the development of ion channel modulators is booming. One exciting target is the Kv1.3 voltage activated potassium channel. Expressed by human T lymphocytes Kv1.3 is involved in proliferation and cytokine secretion. Animal studies have established Kv1.3 as a target for the unmet multiple sclerosis (MS) market. Further key proof of concept data has now emerged demonstrating the selective expression of this channel in myelin-reactive effector memory T cells from MS patients
05 Aug 03
Pharma NewsBytes is LeadDiscovery's summary of news items released from the pharmaceutical and biotech sector over the previous two weeks. This week we feature the FDA's backing of the statin, Crestor; a new agreement based on the development of HDAC inhibitors which could leed to imporved cancer therapeutics; a novel and highly promising approach to metabolic disease announced by Roche; emerging clinical data on what appears to be an effective treatment of primary liver cancer and more.....
29 Jul 03
Faced with rising costs, shortened product lifecycles and an increasing reliance on blockbuster drugs, pharmaceutical companies are turning towards innovative marketing campaigns and new channels to reach an increasingly demanding consumer audience. Offering particular potential, campaign management solutions are being introduced to establish profitable interactions with large numbers of consumers across multiple channels.
29 Jul 03
Although elderly people have a higher incidence of the four major cancers than any other age group, there is a fundamental lack of knowledge regarding the treatment of this demographic, resulting in their under-treatment. Commercial opportunity therefore awaits any pharmaceutical company able to target the development of strategies aimed specifically at elderly patients.
16 Jul 03
This edition of
07 Jul 03
The pharmaceutical industry is currently sinking considerable resources into the treatment of autoimmune disorders. One new candidate target is the histone deacetylase, HDAC7, reviewed in LeadDiscovery’s Target of the Month for July. HDAC7 inhibits Nur77 expression, a key regulator of T cell receptor mediated T cell apoptosis. Blocking HDAC7 can potentialy enhance apoptosis of autoreactive T cells and HDAC7 inhibitors may therefore be candidate treatments of autoimmune disorders.
30 Jun 03
Biogen and Idec Pharmaceuticals are set to merge in a stock-for-stock transaction valued at over $6.6 billion following announcements made earlier this week. The deal will create the third largest biotech firm in the world, yet Wall Street has so far appeared unimpressed by the deal. Even individual analysts seem to be disagreeing as to the strategic sense of the partnership.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.